These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16449534)

  • 41. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
    Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
    J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
    Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Detection of bcr/abl fusion gene changes in patients with chronic myeloid leukemia after allo-HSCT by real-time quantitative reverse transcription polymerase chain reaction and its significance].
    Xue M; Wang HX; Duan LN; Yan HM; Zhu L; Liu J; Ding L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1350-3. PubMed ID: 19099642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Minimal residual disease in chronic myeloid leukaemia.
    Cross NC
    Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
    Sawyers CL; Timson L; Kawasaki ES; Clark SS; Witte ON; Champlin R
    Proc Natl Acad Sci U S A; 1990 Jan; 87(2):563-7. PubMed ID: 2405384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
    Gaiger A; Lion T; Kalhs P; Mitterbauer G; Henn T; Haas O; Födinger M; Kier P; Forstinger C; Quehenberger P
    Leukemia; 1993 Nov; 7(11):1766-72. PubMed ID: 8231244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
    Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia.
    Langabeer SE; Gale RE; Harvey RC; Cook RW; Mackinnon S; Linch DC
    Leukemia; 2002 Mar; 16(3):393-9. PubMed ID: 11896544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of bcr/abl fusion transcripts by semiquantitative multiplex RT-PCR combined with a colormetric assay in Ph positive leukemia.
    Ni H; Nitta M; Komatsu H; Kojima S; Suzuki S; Harada S; Tsuboi K; Banno S; Wakita A; Yazaki M; Ren L; Kato T; Ueda R
    Cancer Lett; 1998 Feb; 124(2):173-80. PubMed ID: 9500207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
    Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
    Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts.
    Langabeer SE; Crampe M; Kelly J; Fadalla K; Connaghan G; Conneally E
    Leuk Res; 2010 Aug; 34(8):e204-5. PubMed ID: 20346507
    [No Abstract]   [Full Text] [Related]  

  • 56. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.
    Savoldo B; Sammarelli G; Dotti G; Garau D; Regazzi E; Cilloni D; Tabilio A; Rizzoli V; Carlo-Stella C
    Leukemia; 1998 Mar; 12(3):434-40. PubMed ID: 9529140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
    Diekmann L; Beelen DW; Quabeck K; Becher R; Schulte Holthausen H; Bützler R; Schaefer UW; Opalka B
    Acta Haematol; 1994; 92(4):169-75. PubMed ID: 7701913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
    Moravcová J; Brdicka R
    Cas Lek Cesk; 2005; 144(1):32-7. PubMed ID: 15789779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
    Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
    Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.